Combination of Temozolomide with Immunocytokine F16-IL2 for the Treatment of Glioblastoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 Aug 26

PMID 20736949

Citations 30

Authors

M Pedretti

C Verpelli

J Marlind

G Bertani

C Sala

D Neri

L Bello

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to the A1 domain of tenascin-C.

Methods: We conducted three preclinical therapy studies, using subcutaneous and intracranial U87MG glioblastoma tumours xenografted in BALB/c nude mice. The same therapeutic schedule was used, consisting of five total administrations every third day, of 0.525 mg temozolomide, 20 microg F16-IL2, the combination, or the control solution.

Results: Immunohistochemical analysis of U87MG xenografts and of human glioblastoma specimens showed selective tumour staining of F16. A quantitative biodistribution confirmed the preferential tumour accumulation of radiolabelled F16-IL2. In the study with subcutaneous xenografts, the combination of F16-IL2 with temozolomide induced complete remission of the animals, which remained tumour free for over 160 days. The same treatment led to a consistent size reduction of intracranial xenografts and to a longer survival of animals. The immunocytokine promoted the recruitment of leukocytes into tumours of both models.

Conclusion: The combined use of temozolomide with F16-IL2 deserves clinical investigations, which will be facilitated by the excellent safety profile in cynomolgus monkeys, and by the fact that F16-IL2 is in clinical trials in patients with cancer.

Citing Articles

IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors.

Wickman E, Lange S, Wagner J, Ibanez J, Tian L, Lu M J Immunother Cancer. 2024; 12(11).

PMID: 39572158 PMC: 11580246. DOI: 10.1136/jitc-2024-009743.

Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.

Prodi E, Neri D, De Luca R Onco Targets Ther. 2024; 17:697-715.

PMID: 39224695 PMC: 11368152. DOI: 10.2147/OTT.S480787.

TNC upregulation promotes glioma tumourigenesis through TDG-mediated active DNA demethylation.

Xu H, Long S, Xu C, Li Z, Chen J, Yang B Cell Death Discov. 2024; 10(1):347.

PMID: 39090080 PMC: 11294444. DOI: 10.1038/s41420-024-02098-w.

Targeted Cytokine Delivery for Cancer Treatment: Engineering and Biological Effects.

Rybchenko V, Aliev T, Panina A, Kirpichnikov M, Dolgikh D Pharmaceutics. 2023; 15(2).

PMID: 36839658 PMC: 9960319. DOI: 10.3390/pharmaceutics15020336.

Matricellular protein tenascin C: Implications in glioma progression, gliomagenesis, and treatment.

Fu Z, Zhu G, Luo C, Chen Z, Dou Z, Chen Y Front Oncol. 2022; 12:971462.

PMID: 36033448 PMC: 9413079. DOI: 10.3389/fonc.2022.971462.

References

Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L . Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol. 2002; 20(3):264-9. DOI: 10.1038/nbt0302-264. View

Newlands E, Stevens M, Wedge S, Wheelhouse R, Brock C . Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997; 23(1):35-61. DOI: 10.1016/s0305-7372(97)90019-0. View

Burnet N, Jefferies S, Benson R, Hunt D, Treasure F . Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds. Br J Cancer. 2005; 92(2):241-5. PMC: 2361853. DOI: 10.1038/sj.bjc.6602321. View

Tijink B, Neri D, Leemans C, Budde M, Dinkelborg L, Stigter-van Walsum M . Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006; 47(7):1127-35. View

Graf M, Prins R, Poulsen G, Merchant R . Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery. J Neuroimmunol. 2003; 140(1-2):49-60. DOI: 10.1016/s0165-5728(03)00167-x. View

Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P . Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998; 273(34):21769-76. DOI: 10.1074/jbc.273.34.21769. View

Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B . Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998; 58(6):1195-201. View

Friedman H, Kerby T, Calvert H . Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000; 6(7):2585-97. View

Birchler M, Viti F, Zardi L, Spiess B, Neri D . Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol. 1999; 17(10):984-8. DOI: 10.1038/13679. View

10.

Dunne J, Lynch S, OFarrelly C, Todryk S, Hegarty J, Feighery C . Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol. 2001; 167(6):3129-38. DOI: 10.4049/jimmunol.167.6.3129. View

11.

Halin C, Gafner V, Villani M, Borsi L, Berndt A, Kosmehl H . Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res. 2003; 63(12):3202-10. View

12.

Santimaria M, Moscatelli G, Viale G, Giovannoni L, Neri G, Viti F . Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003; 9(2):571-9. View

13.

Castellani P, Borsi L, Carnemolla B, Biro A, Dorcaratto A, Viale G . Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol. 2002; 161(5):1695-700. PMC: 1850782. DOI: 10.1016/S0002-9440(10)64446-X. View

14.

Carter P . Potent antibody therapeutics by design. Nat Rev Immunol. 2006; 6(5):343-57. DOI: 10.1038/nri1837. View

15.

Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla R . Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int J Cancer. 2009; 127(1):101-10. DOI: 10.1002/ijc.25018. View

16.

Frey K, Schliemann C, Schwager K, Giavazzi R, Johannsen M, Neri D . The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J Urol. 2010; 184(6):2540-8. DOI: 10.1016/j.juro.2010.07.030. View

17.

Thorpe P . Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004; 10(2):415-27. DOI: 10.1158/1078-0432.ccr-0642-03. View

18.

Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A . Selective targeted delivery of TNFalpha to tumor blood vessels. Blood. 2003; 102(13):4384-92. DOI: 10.1182/blood-2003-04-1039. View

19.

Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre P . Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004; 64(19):6892-9. DOI: 10.1158/0008-5472.CAN-04-1337. View

20.

Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H . Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer. 2005; 116(2):304-13. DOI: 10.1002/ijc.20952. View